Rationalisation of Polypharmacy by the Geriatric Consultation Team

Iatrogenic Disease Clinical Trial

— RASP-GCT  

Official title:

Rationalisation of Polypharmacy by the Geriatric Consultation Team Using the RASP List: a Pilot Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02165618
• Other study ID #: S-54896
• Status: Completed
• Phase: N/A
• First received: May 26, 2014
• Last updated: June 13, 2014
• Start date: January 2014
• Est. completion date: February 2014

Study information

• Verified date: May 2014
• Source: Universitaire Ziekenhuizen Leuven
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belgium: Federal Agency for Medicines and Health Products, FAMHP
• Study type: Interventional

Clinical Trial Summary

Polypharmacy is a common problem in elderly, leading among others to increased adverse drug events. The aim of this pilot study was to evaluate whether a systematic medication evaluation by a geriatric consultation team using the RASP (Rationalisation of drugs on admission by an adjusted STOPP*-list in older patients) list could reduce inappropriate prescribing for elderly admitted patients, admitted to non-geriatric departments.

(* = Screening Tool of Older Persons' potentially inappropriate Prescriptions)

Description:

Polypharmacy and (potentially) inappropriate prescribing is highly prevalent in the older population, associated with increase health care expenditures, morbidity and avoidable adverse events .

The aim of this pilot study was to evaluate whether a systematic medication evaluation by a geriatric consultation team (GCT) using the RASP (Rationalisation of drugs on admission by an adjusted STOPP-list in older patients) list could reduce inappropriate prescribing for older admitted patients, admitted to non-geriatric departments. The GCT could offer the ideal format to deliver the intervention to a broad older hospitalised population.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: February 2014
• Est. primary completion date: February 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 75 Years and older

Eligibility

Inclusion Criteria:

• Admitted to a non-geriatric ward

• 75 years or older

• Dutch speaking

• Consultation by the GCT

Exclusion Criteria:

• End-of-life

• No drugs on admission

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research

Related Conditions & MeSH terms

• Iatrogenic Disease

Intervention

Other:
• Medication review, based on but not limited to the RASP list
Systematic approach: Medication reconciliation Applying the RASP list Expert review (not based on the RASP list) Multidisciplinary discussion

Locations

Country	Name	City	State
Belgium	University Hospitals Leuven	Leuven	Flemish Brabant

Sponsors (1)

Lead Sponsor	Collaborator
Universitaire Ziekenhuizen Leuven

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of medication-related recommendations by the geriatric consultation team.		The number was ascertained at time of discharge from the ward, taking into account an average hospital stay of 14 days.	No
Secondary	Number of potentially inappropriate drugs at discharge, as identified by the RASP list.		The number was ascertained at time of discharge from the ward, taking into account an average hospital stay of 14 days.	No
Secondary	Number of drugs at discharge, relative to the drugs on admission.		The number was ascertained at time of discharge from the ward, taking into account an average hospital stay of 14 days.	No
Secondary	Acceptance rate of the GCT interventions by the treating physician.		Up to 72 hours after the GCT had given its recommendations.	No